HRP980602B1 - Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations containing them - Google Patents
Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations containing themInfo
- Publication number
- HRP980602B1 HRP980602B1 HR980602A HRP980602A HRP980602B1 HR P980602 B1 HRP980602 B1 HR P980602B1 HR 980602 A HR980602 A HR 980602A HR P980602 A HRP980602 A HR P980602A HR P980602 B1 HRP980602 B1 HR P980602B1
- Authority
- HR
- Croatia
- Prior art keywords
- optionally substituted
- alkyl
- aryl
- residue
- heteroaryl
- Prior art date
Links
- 150000002461 imidazolidines Chemical class 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 2
- 239000005977 Ethylene Chemical group 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 1
- 102220644355 Laminin subunit alpha-5_R22N_mutation Human genes 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19751251A DE19751251A1 (de) | 1997-11-19 | 1997-11-19 | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP980602A2 HRP980602A2 (en) | 1999-08-31 |
| HRP980602B1 true HRP980602B1 (en) | 2006-07-31 |
Family
ID=7849203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR980602A HRP980602B1 (en) | 1997-11-19 | 1998-11-18 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations containing them |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US6331552B1 (enExample) |
| EP (1) | EP0918059B1 (enExample) |
| JP (1) | JP4567821B2 (enExample) |
| KR (1) | KR100738820B1 (enExample) |
| CN (1) | CN1330638C (enExample) |
| AR (1) | AR016011A1 (enExample) |
| AT (1) | ATE243708T1 (enExample) |
| AU (1) | AU755893B2 (enExample) |
| BR (1) | BR9804695B1 (enExample) |
| CA (1) | CA2254420C (enExample) |
| CZ (1) | CZ297564B6 (enExample) |
| DE (2) | DE19751251A1 (enExample) |
| DK (1) | DK0918059T3 (enExample) |
| ES (1) | ES2202718T3 (enExample) |
| HR (1) | HRP980602B1 (enExample) |
| HU (1) | HU229481B1 (enExample) |
| ID (1) | ID21305A (enExample) |
| IL (1) | IL127132A (enExample) |
| MY (1) | MY118313A (enExample) |
| NO (1) | NO325303B1 (enExample) |
| NZ (1) | NZ332855A (enExample) |
| PL (1) | PL194692B1 (enExample) |
| PT (1) | PT918059E (enExample) |
| RU (1) | RU2239641C2 (enExample) |
| SI (1) | SI0918059T1 (enExample) |
| SK (1) | SK284851B6 (enExample) |
| TR (1) | TR199802344A2 (enExample) |
| TW (1) | TWI230155B (enExample) |
| ZA (1) | ZA9810543B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| US6723711B2 (en) | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| DE19922462A1 (de) * | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| SK8692002A3 (en) | 1999-12-28 | 2003-06-03 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| GB0010105D0 (en) * | 2000-04-26 | 2000-06-14 | Ml Lab Plc | Cell ablation |
| DE10111877A1 (de) * | 2001-03-10 | 2002-09-12 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE10111876A1 (de) | 2001-03-10 | 2002-09-19 | Aventis Pharma Gmbh | Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe |
| US20030154499A1 (en) * | 2001-06-08 | 2003-08-14 | Monika Wasel-Nielen | Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor |
| AU2002315415A1 (en) * | 2001-06-22 | 2003-01-08 | Aventis Pharmaceuticals Inc. | Chiral preparation of a diastereomeric compound |
| DE10134366A1 (de) * | 2001-07-14 | 2003-01-23 | Aventis Pharma Gmbh | Verfahren zur Herstellung der enantiomeren Formen von 2-substituierten 2-(2,5-Dioxoimidazolidin-l-yl)-essigsäure- Derivaten |
| DE10137595A1 (de) | 2001-08-01 | 2003-02-13 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung |
| EP1474425B9 (en) | 2002-01-07 | 2008-07-02 | Eisai Co., Ltd. | Deazapurines and uses thereof |
| US7691843B2 (en) * | 2002-07-11 | 2010-04-06 | Pfizer Inc. | N-hydroxyamide derivatives possessing antibacterial activity |
| AU2003282920A1 (en) * | 2002-10-04 | 2004-05-04 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
| WO2004083163A1 (ja) * | 2003-03-17 | 2004-09-30 | Ube Industries, Ltd. | ３－アミノ－３－アリールプロピオン酸ｎ－アルキルエステル及びその製造方法並びに光学活性３－アミノ－３－アリールプロピオン酸及びその対掌エステルの製造方法 |
| AP1963A (en) | 2003-05-30 | 2009-03-03 | Ranbaxy Lab Ltd | Substituted pyrrole derivatives and their use as HMG-co inhibitors |
| DE102004009822A1 (de) | 2004-02-28 | 2005-09-15 | Zf Lenksysteme Gmbh | Verfahren zum Betrieb eines Lenksystems mit Signalplausibilisierung |
| AU2006313430B2 (en) | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| WO2008103378A2 (en) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
| AU2009234253C1 (en) | 2008-04-11 | 2015-05-07 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| SG10201701421PA (en) * | 2008-08-22 | 2017-04-27 | Novomer Inc | Catalysts and methods for polymer synthesis |
| DE102009012314A1 (de) | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung |
| PL3326645T3 (pl) | 2010-10-25 | 2020-09-21 | Biogen Ma Inc. | Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM |
| EP3112353A1 (en) * | 2015-06-30 | 2017-01-04 | Studiengesellschaft Kohle MbH | Substituted imidazolium sulfuranes and their use |
| AR114489A1 (es) * | 2018-04-12 | 2020-09-09 | Morphic Therapeutic Inc | ANTAGONISTAS DE LA INTEGRINA a4b7 HUMANA |
| US11292782B2 (en) | 2018-11-30 | 2022-04-05 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
| CN117551696A (zh) * | 2019-08-05 | 2024-02-13 | 宝利普拉斯生物转染公司 | 包含接枝到阳离子聚合物上的三唑化合物的用于将核酸分子转染到细胞中的组合物及其应用 |
| TWI900200B (zh) | 2019-10-16 | 2025-10-01 | 美商莫菲克醫療股份有限公司 | 抑制人類整合素αβ |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE235866C (enExample) | ||||
| DE2937779A1 (de) | 1979-09-19 | 1981-04-09 | Hoechst Ag, 6000 Frankfurt | Aminosaeurederivate und verfahren zu ihrer herstellung |
| DE3044236A1 (de) | 1980-11-25 | 1982-06-16 | Hoechst Ag, 6000 Frankfurt | Aminosaeurederivate und verfahren zu ihrer herstellung |
| FR2487829A2 (fr) | 1979-12-07 | 1982-02-05 | Science Union & Cie | Nouveaux imino acides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
| FR2503155A2 (fr) | 1980-10-02 | 1982-10-08 | Science Union & Cie | Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
| US4350704A (en) | 1980-10-06 | 1982-09-21 | Warner-Lambert Company | Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids |
| EP0046953B1 (de) | 1980-08-30 | 1989-12-06 | Hoechst Aktiengesellschaft | Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung |
| US4344949A (en) | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
| DE3174844D1 (en) | 1980-10-23 | 1986-07-24 | Schering Corp | Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them |
| US4374847A (en) | 1980-10-27 | 1983-02-22 | Ciba-Geigy Corporation | 1-Carboxyalkanoylindoline-2-carboxylic acids |
| DE3226768A1 (de) | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
| CA1341296C (en) | 1981-12-29 | 2001-09-25 | Hansjorg Urbach | 2-azabicycloalkane-3-carboxylic acid derivatives, processes for their preparation, agents containing these compounds and their use |
| DE3210496A1 (de) | 1982-03-23 | 1983-10-06 | Hoechst Ag | Neue derivate bicyclischer aminsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung |
| DE3211397A1 (de) | 1982-03-27 | 1983-11-10 | Hoechst Ag, 6230 Frankfurt | Spiro (4.(3+n))-2-aza-3-carbonsaeure-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| DE3211676A1 (de) | 1982-03-30 | 1983-10-06 | Hoechst Ag | Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung |
| DE3227055A1 (de) | 1982-07-20 | 1984-01-26 | Hoechst Ag, 6230 Frankfurt | Neue derivate der 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure als zwischenstufe und verfahren zu deren herstellung |
| DE3242151A1 (de) | 1982-11-13 | 1984-05-17 | Hoechst Ag, 6230 Frankfurt | Neue derivate tricyclischer aminosaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung, sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung |
| DE3246503A1 (de) | 1982-12-16 | 1984-06-20 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(5.3.0)-decan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
| DE3643012A1 (de) | 1986-12-17 | 1988-06-30 | Hoechst Ag | 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| DE3818850A1 (de) | 1988-06-03 | 1989-12-07 | Hoechst Ag | Oligopeptide mit zyklischen prolin-analogen aminosaeuren |
| DE4009506A1 (de) * | 1990-03-24 | 1991-09-26 | Hoechst Ag | Hydantoinderivate |
| DE4126277A1 (de) * | 1991-08-08 | 1993-02-11 | Cassella Ag | Hydantoinderivate |
| RU2032672C1 (ru) * | 1991-08-20 | 1995-04-10 | Институт физико-органической химии и углехимии им.Л.М.Литвиненко АН Украины | 1,3-бис-(2,3-диакрилоилоксипропил) -5,5-диметил-2,4-имидазолидиндион в качестве модификатора фотополимеризующихся акрилатных композиций |
| DE69309044T3 (de) * | 1992-01-13 | 2004-12-23 | Biogen, Inc., Cambridge | Behandlung von asthma |
| ATE151642T1 (de) * | 1992-02-12 | 1997-05-15 | Biogen Inc | Behandlung für entzündungserkrankung des darmes |
| DE4207254A1 (de) * | 1992-03-07 | 1993-09-09 | Cassella Ag | 4-oxo-2-thioxoimidazolidin-derivate |
| DE4213634A1 (de) * | 1992-04-24 | 1993-10-28 | Cassella Ag | 2,4-Dioxo-imidazolidin-Derivate |
| DE4224414A1 (de) | 1992-07-24 | 1994-01-27 | Cassella Ag | Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung |
| DE4228717A1 (de) | 1992-08-28 | 1994-03-03 | Cassella Ag | Imidazolidin-Derivate |
| SG52262A1 (en) | 1993-01-08 | 1998-09-28 | Tanabe Seiyaku Co | Peptide inhibitors of cell adhesion |
| WO1994016094A2 (en) | 1993-01-12 | 1994-07-21 | Biogen, Inc. | Recombinant anti-vla4 antibody molecules |
| HK1008731A1 (en) | 1993-02-09 | 1999-05-14 | Biogen Idec Ma Inc. | Antibody for the treatment of insulin dependent diabetes |
| DE4308034A1 (de) * | 1993-03-13 | 1994-09-15 | Cassella Ag | Neue Heterocyclen, ihre Herstellung und ihre Verwendung |
| DE4427979A1 (de) * | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung |
| WO1995015973A1 (en) | 1993-12-06 | 1995-06-15 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
| PL181827B1 (pl) | 1994-01-25 | 2001-09-28 | Athena Neurosciences | Nowa humanizowana immunoglobulina specyficznie wiazaca VLA-4, nowy kwas nukleinowy kodujacy lancuch ciezki tej immunoglobuliny i nowy kwas nukleinowy kodujacy lancuch lekki tej immunoglobuliny PL PL |
| CA2193828A1 (en) * | 1994-06-29 | 1996-01-11 | Timothy P. Kogan | Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin |
| US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| DE19515177A1 (de) | 1995-04-28 | 1996-10-31 | Cassella Ag | Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| EP0796855B1 (de) * | 1996-03-20 | 2002-02-06 | Hoechst Aktiengesellschaft | Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| WO1998004913A1 (en) | 1996-07-25 | 1998-02-05 | Biogen, Inc. | Molecular model for vla-4 inhibitors |
| DE19647380A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| PL323130A1 (en) * | 1996-11-15 | 1998-05-25 | Hoechst Ag | Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such |
| DE19647381A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| DE19648053C1 (de) | 1996-11-20 | 1998-03-12 | Siemens Ag | Elektromagnetisches Schaltgerät |
| WO1998042656A1 (en) | 1997-03-21 | 1998-10-01 | Cytel Corporation | Novel compounds |
-
1997
- 1997-11-19 DE DE19751251A patent/DE19751251A1/de not_active Withdrawn
-
1998
- 1998-11-13 PT PT98121670T patent/PT918059E/pt unknown
- 1998-11-13 EP EP98121670A patent/EP0918059B1/de not_active Expired - Lifetime
- 1998-11-13 DE DE59808804T patent/DE59808804D1/de not_active Expired - Lifetime
- 1998-11-13 DK DK98121670T patent/DK0918059T3/da active
- 1998-11-13 SI SI9830509T patent/SI0918059T1/xx unknown
- 1998-11-13 AT AT98121670T patent/ATE243708T1/de active
- 1998-11-13 ES ES98121670T patent/ES2202718T3/es not_active Expired - Lifetime
- 1998-11-16 ID IDP981494A patent/ID21305A/id unknown
- 1998-11-17 NZ NZ332855A patent/NZ332855A/en not_active IP Right Cessation
- 1998-11-17 HU HU9802653A patent/HU229481B1/hu not_active IP Right Cessation
- 1998-11-17 CZ CZ0372698A patent/CZ297564B6/cs not_active IP Right Cessation
- 1998-11-17 AR ARP980105821A patent/AR016011A1/es active IP Right Grant
- 1998-11-17 CA CA002254420A patent/CA2254420C/en not_active Expired - Fee Related
- 1998-11-17 TR TR1998/02344A patent/TR199802344A2/xx unknown
- 1998-11-17 SK SK1580-98A patent/SK284851B6/sk not_active IP Right Cessation
- 1998-11-18 NO NO19985368A patent/NO325303B1/no not_active IP Right Cessation
- 1998-11-18 ZA ZA9810543A patent/ZA9810543B/xx unknown
- 1998-11-18 AU AU92421/98A patent/AU755893B2/en not_active Ceased
- 1998-11-18 BR BRPI9804695-0A patent/BR9804695B1/pt not_active IP Right Cessation
- 1998-11-18 RU RU98120859/04A patent/RU2239641C2/ru not_active IP Right Cessation
- 1998-11-18 MY MYPI98005253A patent/MY118313A/en unknown
- 1998-11-18 JP JP32850298A patent/JP4567821B2/ja not_active Expired - Fee Related
- 1998-11-18 HR HR980602A patent/HRP980602B1/xx not_active IP Right Cessation
- 1998-11-18 IL IL12713298A patent/IL127132A/xx not_active IP Right Cessation
- 1998-11-18 KR KR1019980049376A patent/KR100738820B1/ko not_active Expired - Fee Related
- 1998-11-19 CN CNB981225195A patent/CN1330638C/zh not_active Expired - Fee Related
- 1998-11-19 PL PL329790A patent/PL194692B1/pl unknown
- 1998-12-04 TW TW087118969A patent/TWI230155B/zh not_active IP Right Cessation
-
2000
- 2000-03-01 US US09/516,587 patent/US6331552B1/en not_active Expired - Lifetime
-
2001
- 2001-09-14 US US09/952,028 patent/US6521654B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP980602B1 (en) | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations containing them | |
| CA2305313A1 (en) | Acylsulfamoylbenzamides, crop protection compositions comprising them, and processes for their preparation | |
| ES2095283T3 (es) | Compuestos peptidicos, procedimiento para su preparacion y composicion farmaceutica que los contiene. | |
| ES8802620A1 (es) | Procedimiento para la obtencion de lipopeptidos | |
| MY137301A (en) | Peptide analogs as irreversible interleukin-1b protease inhibitors | |
| IE780094L (en) | Amino acid derivatives | |
| TW326040B (en) | Substituted 5-membered ring heterocycles, their preparation and their use | |
| ATE342927T1 (de) | Nicht-elastomere polyurethanzusammensetzungen | |
| HUP9903166A2 (hu) | Gyógyászati készítmények arterioszklerózis megelőzésére vagy kezelésére | |
| IL104716A (en) | 7-1-oxo-2- (substituted mercapto)-3- phenylpropyl) amino| octahydro-6-pyrido £2, 1-a| benzazepine- 4-carboxylic acid derivatives and analogs, their preparation and pharmaceutical compositions containing them for inhibiting enkephalinase and ace | |
| ATE423562T1 (de) | Alpha-ketoamidhaltige multikatalytische protease inhibitoren | |
| IE812974L (en) | Tri-,tetra- and penta peptides | |
| SE7714660L (sv) | Aminosockerderivat, sett for framstellning derav samt anvendning derav som lekemedel | |
| ES8200353A1 (es) | Procedimiento para la obtencion de amidas de acido tetrazo- liloxicarboxilico de efecto herbicida | |
| HUP0003847A2 (hu) | Az N-[N-(3,3-dimetil-butil)-L-alfa-aszparagil]-L-fenil-alanin-1-metil-észter bázikus sói | |
| BR9812767A (pt) | Complexos metálicos de 1-metil éster de n-[n-(3,3-dimetilbutil)-l-alfa-aspartil]-l-fenilalanina | |
| ES467697A1 (es) | Procedimiento para la obtencion de protectores contra la in-flamacion a base de derivados del acido fosfonocarboxilico | |
| ATE194377T1 (de) | Klebstoffe | |
| HUP9900661A2 (hu) | A sejtek mitogenezisének és motogenezisének fehérje antagonistái és azok terápiás célú felhasználása | |
| HUP9802749A2 (hu) | Pirrolszármazékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0001058A2 (hu) | 5-Hidroxi-metil-2-amino-tetralinok mint szív-érrendszerre ható szerek, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| NZ504305A (en) | Use of ketolides for preparing arterial thrombotic complications related to atherosclerosis | |
| ES2054904T3 (es) | Procedimiento para la preparacion de peptidos con actividad inhibidora de sistemas enzimaticos. | |
| NO983527D0 (no) | Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler | |
| NZ238949A (en) | Substituted tartaric acid salts of 26-((2-dialkylaminoalkyl)sulphonyl)pristinamycins ii b and antibacterial compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH, DE |
|
| PNAN | Change of the applicant name, address/residence |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, DE |
|
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20141006 Year of fee payment: 17 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20151118 |